APELLIS PHARMACTDL Revenue vs. Cash Flow From Operations
| 1JK Stock | EUR 31.22 0.02 0.06% |
For APELLIS PHARMACTDL profitability analysis, we use financial ratios and fundamental drivers that measure the ability of APELLIS PHARMACTDL to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well APELLIS PHARMACTDL 0001 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between APELLIS PHARMACTDL's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of APELLIS PHARMACTDL 0001 over time as well as its relative position and ranking within its peers.
APELLIS |
APELLIS PHARMACTDL 0001 Cash Flow From Operations vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining APELLIS PHARMACTDL's current stock value. Our valuation model uses many indicators to compare APELLIS PHARMACTDL value to that of its competitors to determine the firm's financial worth. APELLIS PHARMACTDL 0001 is the top company in revenue category among its peers. It is rated below average in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the APELLIS PHARMACTDL's earnings, one of the primary drivers of an investment's value.APELLIS Revenue vs. Competition
APELLIS PHARMACTDL 0001 is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 26.16 Trillion. APELLIS PHARMACTDL adds roughly 113.05 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.
APELLIS Cash Flow From Operations vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
APELLIS PHARMACTDL |
| = | 113.05 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
APELLIS PHARMACTDL |
| = | (239.85 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
APELLIS Cash Flow From Operations Comparison
APELLIS PHARMACTDL is currently under evaluation in cash flow from operations category among its peers.
APELLIS PHARMACTDL Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in APELLIS PHARMACTDL, profitability is also one of the essential criteria for including it into their portfolios because, without profit, APELLIS PHARMACTDL will eventually generate negative long term returns. The profitability progress is the general direction of APELLIS PHARMACTDL's change in net profit over the period of time. It can combine multiple indicators of APELLIS PHARMACTDL, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.
APELLIS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on APELLIS PHARMACTDL. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of APELLIS PHARMACTDL position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the APELLIS PHARMACTDL's important profitability drivers and their relationship over time.
Use APELLIS PHARMACTDL in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if APELLIS PHARMACTDL position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in APELLIS PHARMACTDL will appreciate offsetting losses from the drop in the long position's value.APELLIS PHARMACTDL Pair Trading
APELLIS PHARMACTDL 0001 Pair Trading Analysis
The ability to find closely correlated positions to APELLIS PHARMACTDL could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace APELLIS PHARMACTDL when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back APELLIS PHARMACTDL - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling APELLIS PHARMACTDL 0001 to buy it.
The correlation of APELLIS PHARMACTDL is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as APELLIS PHARMACTDL moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if APELLIS PHARMACTDL 0001 moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for APELLIS PHARMACTDL can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your APELLIS PHARMACTDL position
In addition to having APELLIS PHARMACTDL in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in APELLIS Stock
To fully project APELLIS PHARMACTDL's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of APELLIS PHARMACTDL 0001 at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include APELLIS PHARMACTDL's income statement, its balance sheet, and the statement of cash flows.